Litigation Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

Docket		Date Filed	2013-02-28
Court	District Court, S.D. Indiana	Date Terminated	2013-06-24
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	None	Referred To	Denise K Larue
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-02-28				External link to document

ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC. (1:13-cv-00335): Litigation Summary, Patent/Claim Snapshot, and Exclusivity/Entry Impact

Last updated: July 18, 2026

Executive summary: The case Eli Lilly and Co. v. Accord Healthcare Inc. (US District Court, 1:13-cv-00335) is a patent infringement dispute tied to a Lilly-listed FDA product and Accord’s proposed generic. The litigation posture and outcome determine (1) whether Accord could launch during the asserted patent term, (2) which Lilly patents survived the window for a drug-entry challenge, and (3) how later Paragraph IV and settlement-driven entry risks were priced for investors and competitors.

Limits note (compliance with input constraints): The request provides only the case caption and docket number. A complete, accurate infringement-limitation analysis requires the underlying complaint, asserted patent list, claim chart themes, claim construction rulings, trial record or dispositive motions, and final judgment/order text. Without those case-document facts, producing a correct litigation summary (particular patents-in-suit, adjudicated claims, dates, and entry consequences) would risk factual error.

Nothing follows.